BioMedNewsBreaks

ThursdayJul 15, 2021 2:52 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Premieres New Clubhouse Show Titled ‘Activate Your Superhuman Mind’

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, announced that its new weekly talk show is scheduled to premiere on Clubhouse, a new type of social network based on voice. The increasingly popular channel enables millions of people around the world to gather to talk, listen and learn from each other in real time. The talk show, titled “Activate Your Superhuman Mind,” will cover a range of topics focused on achieving superior mental focus and energy. A new episode will be broadcast every Thursday, from 7:30–8:30 p.m. ET. The most recent episode, called…

Continue Reading

ThursdayJul 15, 2021 12:58 pm

BioMedNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of Antiviral Drug Molecular Characterization Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced the results of its antiviral drug molecular characterization study. Lexaria worked with the National Research Council (“NRC”), Canada’s premier federally funded research organization, to conduct the study. Results from the NRC confirm the study objectives, including demonstrating that the company’s proprietary DehydraTECH(TM) processing and formulation technology does not create a covalently bonded new molecular entity (“NME”). In addition, the study confirmed that each of the five drugs tested remained stable without undergoing any change in chemical structure. The five drugs included remdesivir, ebastine, bepridil, rupintrivir and colchicine. The…

Continue Reading

WednesdayJul 14, 2021 11:14 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Further Research in Psychedelic Treatment for Mental Health

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has partnered with Ehave Inc., a provider of digital therapeutics for the psychedelic and mental health sectors. The partnership is intended to change the fact that although there are currently 250 identified biochemical markers about a broad range of the body’s organic system and how they function, the approach to utilize them to improve diagnostic accuracy and patient outcomes remains challenging for psychiatric disorders. Additionally, experts caution that even though a potential breakthrough has been found pertaining to treating a range of mental illnesses, which could…

Continue Reading

TuesdayJul 13, 2021 1:15 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Covid-ID Lab Filling Existing Market Gap

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25. The company is likely to benefit from the country’s regulatory requirements and the government’s initiative that qualifies every resident to at least one free COVID-19 test per week. “Covid-ID Lab combines the accuracy of a PCR test, the gold standard for diagnosis, with the speed of an antigen test, thereby filling the existing market gap between centralized, automated PCR…

Continue Reading

TuesdayJul 13, 2021 11:48 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Promising Study Results for Game-Changing Technology

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of the 74 adult patients treated with the company’s FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms, defined as patients having an Apnea Hypopnea Index (“AHI”) score of less than five post-treatment. “We are not aware of any treatment for…

Continue Reading

MondayJul 12, 2021 10:27 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Fast Track Designation for Lead Investigational Drug

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead investigational drug, Berubicin, has been granted fast track designation by the U.S. Food and Drug Administration (“FDA”). That announcement came from WPD Pharmaceuticals Inc.(CSE: WBIO) (FSE: 8SV1), a clinical-stage pharmaceutical company that licenses Berubicin from CNSP. Berubicin is designed for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). According to the announcement, fast track designation allows the company to interact more frequently with the FDA for the purposes of expediting the development and review process; the designation is reserved for drugs with the potential to address unmet medical need in the treatment of serious or life-threatening…

Continue Reading

FridayJul 09, 2021 11:10 am

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiaries Showcase Products, Services at BIO Digital

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech partnering event held virtually on June 10-11 and 14-18, 2021, through its three subsidiaries. “While informative, the thrust of attending for companies like that of Predictive Oncology is networking and one-on-one sessions that can result in new partnerships or customers,” reads a recent article. “‘In previous conferences, Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their…

Continue Reading

FridayJul 09, 2021 10:18 am

BioMedNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in William Blair Biotech Focus Conference

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be part of this year’s online William Blair Biotech Focus Conference. VTGN management will participate in a panel discussion titled “Updates in Neuropsych.” Key executives will also be available for one-on-one meetings throughout the virtual conference, which will be held July 15. The panel discussion is slated to begin at 9 a.m. PT. In the announcement, VTGN noted that the panel…

Continue Reading

ThursdayJul 08, 2021 12:47 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Announces Ultimate Brain Nutrients ACTIVATE, a Breakthrough Nutraceutical Formulation

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain health, has unveiled a game-changing nutraceutical formulation: Ultimate Brain Nutrients ACTIVATE(TM) (“UBN”). According to the company, clinical studies indicate that the proprietary formulation naturally increases key brain activity by as much as 46%. Other results from studies show that ACTIVATE significantly improves human cognitive behavior and mental focus by activating areas of the brain that are key in attention, memory, mood and quick reaction times. HYEX has devoted more than two decades in research on the formulation, which included approximately 100 clinical studies…

Continue Reading

ThursdayJul 08, 2021 11:04 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Brings Cutting-Edge Tech to the Neurology Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cutting-edge tech that bridges the widening gap in access to quality care. The company’s clinical-grade neurological devices, NeuroCap(TM) and NeuroEEG(TM), are portable, cost-efficient, easy-to-use, and allow for long-term monitoring. This technology will be part of a ketamine clinical study conducted by Ehave Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. “Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the areas impacted,” reads a recent article. “BRSF’s…

Continue Reading